<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34787691</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>14</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1435-702X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>260</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie</Title>
          <ISOAbbreviation>Graefes Arch Clin Exp Ophthalmol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The risk factors for Graves' ophthalmopathy.</ArticleTitle>
        <Pagination>
          <StartPage>1043</StartPage>
          <EndPage>1054</EndPage>
          <MedlinePgn>1043-1054</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00417-021-05456-x</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">This review aimed to provide an overview of current research into the risk factors for Graves' ophthalmopathy (GO).</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">To find information about the risk factors for GO, the research database PubMed was searched and relevant articles were obtained to extract information about risk factors.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Smoking has been widely accepted as an important risk factor and cigarette smoking cessation has been shown to improve the outcome and decrease the onset of GO. Radioactive iodine on the thyroid may induce hyperthyroidism and increase the occurrence of GO. Selenium deficiency is a risk factor for GO and the supplementation of selenium has been an adjuvant therapy. Decreasing stressful life events (SLE) may help improve GO. Imbalance in intestinal flora is essential to GO, with Yersinia enterocolitica and Escherichia coli both increased in the digestive tract of the individual with GO. In addition, controlling serum cholesterol may help improve GO since adipogenesis is an important pathological change in its pathogenesis. Considering the correlation between Graves' disease and GO, maintaining normal thyroid function hormone level is the first-line therapeutic strategy to prevent progression of GO. An increase in antibodies such as TSHR and IGF-1R is the main predictor of GO. Besides, gender and gene polymorphism are also risk factors towards GO.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Risk factors for GO arise from five sources: physical and chemical environment, social-psychological environment, biological environment, the human organism, and genetic codes. Risk factors within these categories may interact with each other and their mechanisms in promoting the development of GO are complex. Research into risk factors for GO may promote emerging fields related to GO such as control of autoantibodies and intestinal microbiota.</AbstractText>
          <CopyrightInformation>© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Cao</LastName>
            <ForeName>Jiamin</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, Third Xiangya Hospital, Central South University, Yuelu District, 138 Tongzipo Road, Changsha, 410013, Hunan, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Su</LastName>
            <ForeName>Yuhe</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Changsha, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Zhuokun</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, Third Xiangya Hospital, Central South University, Yuelu District, 138 Tongzipo Road, Changsha, 410013, Hunan, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Chen</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, Third Xiangya Hospital, Central South University, Yuelu District, 138 Tongzipo Road, Changsha, 410013, Hunan, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xiong</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <Identifier Source="ORCID">0000-0002-3017-9895</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, Third Xiangya Hospital, Central South University, Yuelu District, 138 Tongzipo Road, Changsha, 410013, Hunan, People's Republic of China. weixiong420@csu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Graefes Arch Clin Exp Ophthalmol</MedlineTA>
        <NlmUniqueID>8205248</NlmUniqueID>
        <ISSNLinking>0721-832X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007457">Iodine Radioisotopes</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D049970" MajorTopicYN="Y">Graves Ophthalmopathy</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006980" MajorTopicYN="Y">Hyperthyroidism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007457" MajorTopicYN="N">Iodine Radioisotopes</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013964" MajorTopicYN="Y">Thyroid Neoplasms</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Environment</Keyword>
        <Keyword MajorTopicYN="N">Genetic codes</Keyword>
        <Keyword MajorTopicYN="N">Graves’ ophthalmopathy</Keyword>
        <Keyword MajorTopicYN="N">Human organism</Keyword>
        <Keyword MajorTopicYN="N">Risk factor</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>17</Day>
          <Hour>12</Hour>
          <Minute>25</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34787691</ArticleId>
        <ArticleId IdType="doi">10.1007/s00417-021-05456-x</ArticleId>
        <ArticleId IdType="pii">10.1007/s00417-021-05456-x</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Mohyi M, Smith TJ (2018) 40 YEARS OF IGF1: IGF1 receptor and thyroid-associated ophthalmopathy. J Mol Endocrinol 61(1):T29–T43. https://doi.org/10.1530/JME-17-0276</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/JME-17-0276</ArticleId>
            <ArticleId IdType="pubmed">29273685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bahn RS (2010) Graves’ Ophthalmopathy New Engl J Med 362(8):726–738. https://doi.org/10.1056/NEJMra0905750</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra0905750</ArticleId>
            <ArticleId IdType="pubmed">20181974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, Marino M, Vaidya B, Wiersinga WM (2021) The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol 185(4):G43–G67. https://doi.org/10.1530/EJE-21-0479</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/EJE-21-0479</ArticleId>
            <ArticleId IdType="pubmed">34297684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bouchard P, Carra MC, Boillot A, Mora F, Range H (2017) Risk factors in periodontology: a conceptual framework. J Clin Periodontol 44(2):125–131. https://doi.org/10.1111/jcpe.12650</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jcpe.12650</ArticleId>
            <ArticleId IdType="pubmed">27862138</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grzybowski A, Nita M (2017) Smoking and eye pathologies. A systemic review. Part II. Retina Diseases, Uveitis Optic Neuropathies, Thyroid-Associated Orbitopathy. Curr Pharm Design 23(4):639–654. https://doi.org/10.2174/1381612823666170111095723</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1381612823666170111095723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roos JCP, Paulpandian V, Murthy R (2019) Serial TSH-receptor antibody levels to guide the management of thyroid eye disease: the impact of smoking, immunosuppression, radio-iodine, and thyroidectomy. Eye 33(2):212–217. https://doi.org/10.1038/s41433-018-0242-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41433-018-0242-9</ArticleId>
            <ArticleId IdType="pubmed">30401900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kau H, Wu S, Tsai C, Liu CJ, Wei Y (2016) Cigarette Smoke Extract-Induced Oxidative Stress and Fibrosis-Related Genes Expression in Orbital Fibroblasts from Patients with Graves’ Ophthalmopathy. Oxid Med Cell Longev 2016:1–10. https://doi.org/10.1155/2016/4676289</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2016/4676289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wiersinga WM, Regensburg NI, Mourits MP (2013) Differential involvement of orbital fat and extraocular muscles in graves’ ophthalmopathy. Eur Thyroid J 2(1):14–21. https://doi.org/10.1159/000348246</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000348246</ArticleId>
            <ArticleId IdType="pubmed">24783034</ArticleId>
            <ArticleId IdType="pmc">3821503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chng CL, Lai OF, Chew CS, Peh YP, Fook-Chong SM, Seah LL, Khoo DH (2014) Hypoxia increases adipogenesis and affects adipocytokine production in orbital fibroblasts-a possible explanation of the link between smoking and Graves’ ophthalmopathy. Int J Ophthalmol-Chi 7(3):403–407. https://doi.org/10.3980/j.issn.2222-3959.2014.03.03</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3980/j.issn.2222-3959.2014.03.03</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Görtz G, Horstmann M, Aniol B, Reyes BD, Fandrey J, Eckstein A, Berchner-Pfannschmidt U (2016) Hypoxia-Dependent HIF-1 Activation Impacts on Tissue Remodeling in Graves’ Ophthalmopathy—Implications for Smoking. J Clin Endocrinol Metab 101(12):4834–4842. https://doi.org/10.1210/jc.2016-1279</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2016-1279</ArticleId>
            <ArticleId IdType="pubmed">27610652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Planck T, Shahida B, Parikh H, Ström K, Åsman P, Brorson H, Hallengren B, Lantz M (2014) Smoking Induces Overexpression of Immediate Early Genes in Active Graves’ Ophthalmopathy. Thyroid 24(10):1524–1532. https://doi.org/10.1089/thy.2014.0153</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2014.0153</ArticleId>
            <ArticleId IdType="pubmed">25135760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Regensburg NI, Wiersinga WM, Berendschot TTJM, Saeed P, Mourits MP (2011) Effect of Smoking on Orbital Fat and Muscle Volume in Graves’ Orbitopathy. Thyroid 21(2):177–181. https://doi.org/10.1089/thy.2010.0218</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2010.0218</ArticleId>
            <ArticleId IdType="pubmed">21142817</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sadeghi-Tari A, Jamshidian-Tehrani M, Nabavi A, Sharif-Kashani S, Elhami E, Hassanpour N, Ameli Zamani K (2016) Effect of smoking on retrobulbar blood flow in thyroid eye disease. Eye (London) 30(12):1573–1578. https://doi.org/10.1038/eye.2016.184</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/eye.2016.184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matheis N, Lantz M, Grus FH, Ponto KA, Wolters D, Brorson H, Planck T, Shahida B, Pitz S, Pfeiffer N, Kahaly GJ (2015) Proteomics of Orbital Tissue in Thyroid-Associated Orbitopathy. J Clin Endocrinol Metab 100(12):E1523–E1530. https://doi.org/10.1210/jc.2015-2976</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2015-2976</ArticleId>
            <ArticleId IdType="pubmed">26451909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xing L, Ye L, Zhu W, Shen L, Huang F, Jiao Q, Zhou X, Wang S, Wang W, Ning G (2015) Smoking was associated with poor response to intravenous steroids therapy in Graves’ ophthalmopathy. Brit J Ophthalmol 99(12):1686–1691. https://doi.org/10.1136/bjophthalmol-2014-306463</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bjophthalmol-2014-306463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Czarnywojtek A, Komar-Rychlicka K, Zgorzalewicz-Stachowiak M, Sawicka-Gutaj N, Woliński K, Gut P, Płazinska M, Torlińska B, Florek E, Waligórska-Stachura J, Ruchała M (2016) Efficacy and safety of radioiodine therapy for mild Graves ophthalmopathy depending on cigarette consumption: a 6‑month follow‑up. Polish Archives of Internal Medicine 126(10):746–753. https://doi.org/10.20452/pamw.3505</Citation>
        </Reference>
        <Reference>
          <Citation>Woo YJ, Kim JW, Yoon JS (2017) Preoperative clinical features of reactivated of Graves’ orbitopathy after orbital decompression. Eye 31(4):643–649. https://doi.org/10.1038/eye.2016.304</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/eye.2016.304</ArticleId>
            <ArticleId IdType="pubmed">28060361</ArticleId>
            <ArticleId IdType="pmc">5396009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li HX, Xiang N, Hu WK, Jiao XL (2016) Relation between therapy options for Graves’ disease and the course of Graves’ ophthalmopathy: a systematic review and meta-analysis. J Endocrinol Invest 39(11):1225–1233. https://doi.org/10.1007/s40618-016-0484-y</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40618-016-0484-y</ArticleId>
            <ArticleId IdType="pubmed">27220843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tay WL, Tong A, Hui K, Tang Y, Chng CL (2017) Radioiodine associated de novo Graves’ opthalmopathy in an Asian cohort. Hell J Nucl Med 20(3):227–231. https://doi.org/10.1967/s002449910606</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1967/s002449910606</ArticleId>
            <ArticleId IdType="pubmed">29177260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watanabe N, Noh JY, Kozaki A, Iwaku K, Sekiya K, Kosuga Y, Matsumoto M, Suzuki M, Yoshihara A, Ohye H, Kobayashi S, Kunii Y, Mukasa K, Sugino K, Inoue T, Ito K (2015) Radioiodine-Associated Exacerbation of Graves’ Orbitopathy in the Japanese Population: Randomized Prospective Study. J Clin Endocrinol Metab 100(7):2700–2708. https://doi.org/10.1210/jc.2014-4542</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2014-4542</ArticleId>
            <ArticleId IdType="pubmed">25965082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Louvet C, De Bellis A, Pereira B, Bournaud C, Kelly A, Maqdasy S, Roche B, Desbiez F, Borson-Chazot F, Tauveron I, Batisse-Lignier M (2016) Time course of Graves’ orbitopathy after total thyroidectomy and radioiodine therapy for thyroid cancer. Medicine 95(48):e5474. https://doi.org/10.1097/MD.0000000000005474</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MD.0000000000005474</ArticleId>
            <ArticleId IdType="pubmed">27902601</ArticleId>
            <ArticleId IdType="pmc">5134772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Träisk F, Tallstedt L, Abraham-Nordling M, Andersson T, Berg G, Calissendorff J, Hallengren B, Hedner P, Lantz M, Nyström E, Ponjavic V, Taube A, Törring O, Wallin G, Åsman P, Lundell G, Thyroid SGOT, The TSGO, (2009) Thyroid-Associated Ophthalmopathy after Treatment for Graves’ Hyperthyroidism with Antithyroid Drugs or Iodine-131. J Clin Endocrinol Metab 94(10):3700–3707. https://doi.org/10.1210/jc.2009-0747</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2009-0747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Czarnywojtek A, Zgorzalewicz-Stachowiak M, Budny B, Wasko R, Florek E, Szczepanek E, Komar-Rychlicka K, Waligorska-Stachura J, Kurdybacha P, Miechowicz I, Ruchala M (2013) The influence of radioiodine therapy on ocular changes and their relation to urine cotinine level in patients with Graves’ Ophthalmopathy. Neuro Endocrinol Lett 34(3):241–248</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23685424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khong JJ, Goldstein RF, Sanders KM, Schneider H, Pope J, Burdon KP, Craig JE, Ebeling PR (2014) Serum selenium status in Graves’ disease with and without orbitopathy: a case-control study. Clin Endocrinol 80(6):905–910. https://doi.org/10.1111/cen.12392</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cen.12392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Federige MAF, Romaldini JH, Miklos ABPP, Koike MK, Takei K, Portes EDS (2017) Serum selenium and selenoprotein-P levels in autoimmune thyroid diseases patients in a select center: a transversal study. Archives of Endocrinology and Metabolism 61(6):600–607. https://doi.org/10.1590/2359-3997000000309</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1590/2359-3997000000309</ArticleId>
            <ArticleId IdType="pubmed">29412385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, Altea MA, Nardi M, Pitz S, Boboridis K, Sivelli P, von Arx G, Mourits MP, Baldeschi L, Bencivelli W, Wiersinga W (2011) Selenium and the Course of Mild Graves’ Orbitopathy. New Engl J Med 364(20):1920–1931. https://doi.org/10.1056/NEJMoa1012985</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1012985</ArticleId>
            <ArticleId IdType="pubmed">21591944</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rotondo Dottore G, Chiarini R, De Gregorio M, Leo M, Casini G, Cestari L, Sellari-Franceschini S, Nardi M, Vitti P, Marcocci C, Marinò M (2017) Selenium rescues orbital fibroblasts from cell death induced by hydrogen peroxide: another molecular basis for the effects of selenium in graves’ orbitopathy. Endocrine 58(2):386–389. https://doi.org/10.1007/s12020-016-1226-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12020-016-1226-9</ArticleId>
            <ArticleId IdType="pubmed">28097622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rotondo Dottore G, Leo M, Casini G, Latrofa F, Cestari L, Sellari-Franceschini S, Nardi M, Vitti P, Marcocci C, Marinò M (2017) Antioxidant Actions of Selenium in Orbital Fibroblasts: A Basis for the Effects of Selenium in Graves’ Orbitopathy. Thyroid 27(2):271–278. https://doi.org/10.1089/thy.2016.0397</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2016.0397</ArticleId>
            <ArticleId IdType="pubmed">27824294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang G, Fu Y, Lu X, Wang M, Dong H, Li Q (2018) The interactive effects of genetic polymorphisms within LFA-1/ICAM-1/GSK-3β pathway and environmental hazards on the development of Graves opthalmopathy. Exp Eye Res 174:161–172. https://doi.org/10.1016/j.exer.2018.05.022</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.exer.2018.05.022</ArticleId>
            <ArticleId IdType="pubmed">29800560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frisch M, Nielsen NM, Pedersen BV (2014) Same-sex marriage, autoimmune thyroid gland dysfunction and other autoimmune diseases in Denmark 1989–2008. Eur J Epidemiol 29(1):63–71. https://doi.org/10.1007/s10654-013-9869-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10654-013-9869-9</ArticleId>
            <ArticleId IdType="pubmed">24306355</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Topcu CB, Celik O, Tasan E (2012) Effect of stressful life events on the initiation of graves’ disease. Int J Psychiat Clin 16(4):307–311. https://doi.org/10.3109/13651501.2011.631016</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/13651501.2011.631016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kahaly GJ, Petrak F, Hardt J, Pitz S, Egle UT (2005) Psychosocial morbidity of Graves’ orbitopathy. Clin Endocrinol (Oxf) 63(4):395–402. https://doi.org/10.1111/j.1365-2265.2005.02352.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2265.2005.02352.x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang G, Fu Y, Lu X, Wang M, Dong H, Li Q (2018) The interactive effects of genetic polymorphisms within LFA-1/ICAM-1/GSK-3β pathway and environmental hazards on the development of Graves’ opthalmopathy. Exp Eye Res 174:161–172. https://doi.org/10.1016/j.exer.2018.05.022</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.exer.2018.05.022</ArticleId>
            <ArticleId IdType="pubmed">29800560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Edmunds MR, Huntbach JA, Durrani OM (2014) Are Ethnicity, Social Grade, and Social Deprivation Associated With Severity of Thyroid-Associated Ophthalmopathy? Ophthalmic Plast Reconstr Surg 30(3):241–245. https://doi.org/10.1097/IOP.0000000000000077</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/IOP.0000000000000077</ArticleId>
            <ArticleId IdType="pubmed">24608325</ArticleId>
            <ArticleId IdType="pmc">4014637</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Köhling HL, Plummer SF, Marchesi JR, Davidge KS, Ludgate M (2017) The microbiota and autoimmunity: Their role in thyroid autoimmune diseases. Clin Immunol 183:63–74. https://doi.org/10.1016/j.clim.2017.07.001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clim.2017.07.001</ArticleId>
            <ArticleId IdType="pubmed">28689782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bassi V, Santinelli C, Iengo A, Romano C (2010) Identification of a Correlation between Helicobacter pylori Infection and Graves’ Disease. Helicobacter 15(6):558–562. https://doi.org/10.1111/j.1523-5378.2010.00802.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1523-5378.2010.00802.x</ArticleId>
            <ArticleId IdType="pubmed">21073613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hargreaves CE, Grasso M, Hampe CS, Stenkova A, Atkinson S, Joshua GWP, Wren BW, Buckle AM, Dunn-Walters D, Banga JP (2013) Yersinia enterocolitica Provides the Link between Thyroid-Stimulating Antibodies and Their Germline Counterparts in Graves’ Disease. J Immunol 190(11):5373–5381. https://doi.org/10.4049/jimmunol.1203412</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1203412</ArticleId>
            <ArticleId IdType="pubmed">23630351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang GC, Collison KS, McGregor AM, Banga JP (1992) Expression of a human thyrotrophin receptor fragment in Escherichia coli and its interaction with the hormone and autoantibodies from patients with Graves’ disease. J Mol Endocrinol 8(2):137–144. https://doi.org/10.1677/jme.0.0080137</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1677/jme.0.0080137</ArticleId>
            <ArticleId IdType="pubmed">1515018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi TT, Xin Z, Hua L, Zhao RX, Yang YL, Wang H, Zhang S, Liu W, Xie RR (2019) Alterations in the intestinal microbiota of patients with severe and active Graves’ orbitopathy: a cross-sectional study. J Endocrinol Invest 42(8):967–978. https://doi.org/10.1007/s40618-019-1010-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40618-019-1010-9</ArticleId>
            <ArticleId IdType="pubmed">30674011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masetti G, Moshkelgosha S, Kohling HL, Covelli D, Banga JP, Berchner-Pfannschmidt U, Horstmann M, Diaz-Cano S, Goertz GE, Plummer S, Eckstein A, Ludgate M, Biscarini F, Marchesi JR (2018) Gut microbiota in experimental murine model of Graves’ orbitopathy established in different environments may modulate clinical presentation of disease. Microbiome 6(1):97. https://doi.org/10.1186/s40168-018-0478-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40168-018-0478-4</ArticleId>
            <ArticleId IdType="pubmed">29801507</ArticleId>
            <ArticleId IdType="pmc">5970527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshiuchi K, Kumano H, Nomura S, Yoshimura H, Ito K, Kanaji Y, Ohashi Y, Kuboki T, Suematsu H (1998) Stressful Life Events and Smoking Were Associated With Graves’ Disease in Women, but Not in Men. Psychosom Med 60(2):182–185. https://doi.org/10.1097/00006842-199803000-00013</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00006842-199803000-00013</ArticleId>
            <ArticleId IdType="pubmed">9560867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woo KI, Kim Y, Lee SY (2013) Prevalence and Risk Factors for Thyroid Eye Disease among Korean Dysthyroid Patients. Korean J Ophthalmol 27(6):397. https://doi.org/10.3341/kjo.2013.27.6.397</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3341/kjo.2013.27.6.397</ArticleId>
            <ArticleId IdType="pubmed">24311923</ArticleId>
            <ArticleId IdType="pmc">3849301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lim SL, Lim AKE, Mumtaz M, Hussein E, Wan Bebakar WM, Khir AS (2008) Prevalence, Risk Factors, and Clinical Features of Thyroid-Associated Ophthalmopathy in Multiethnic Malaysian Patients with Graves’ Disease. Thyroid 18(12):1297–1301. https://doi.org/10.1089/thy.2008.0044</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2008.0044</ArticleId>
            <ArticleId IdType="pubmed">19012471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schlüter A, Flögel U, Diaz-Cano S, Görtz G, Stähr K, Oeverhaus M, Plöhn S, Mattheis S, Moeller LC, Lang S, Bechrakis NE, Banga JP, Eckstein A, Berchner-Pfannschmidt U (2018) Graves’ orbitopathy occurs sex-independently in an autoimmune hyperthyroid mouse model. Sci Rep-Uk 8(1):13096. https://doi.org/10.1038/s41598-018-31253-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-018-31253-4</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Z, Cestari DM, Fortin E (2018) Thyroid eye disease. Curr Opin Ophthalmol 29(6):528–534. https://doi.org/10.1097/ICU.0000000000000529</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/ICU.0000000000000529</ArticleId>
            <ArticleId IdType="pubmed">30124533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ye XZ, Huang SS, Liu J, Lu B, Shao JQ (2019) High serum cholesterol: a novel risk factor for thyroid associated ophthalmopathy? Zhonghua Nei Ke Za Zhi 58(11):823–825. https://doi.org/10.3760/cma.j.issn.0578-1426.2019.11.007</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3760/cma.j.issn.0578-1426.2019.11.007</ArticleId>
            <ArticleId IdType="pubmed">31665858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lanzolla G, Sabini E, Profilo MA, Mazzi B, Sframeli A, Rocchi R, Menconi F, Leo M, Nardi M, Vitti P, Marcocci C, Marinò M (2018) Relationship between serum cholesterol and Graves’ orbitopathy (GO): a confirmatory study. J Endocrinol Invest 41(12):1417–1423. https://doi.org/10.1007/s40618-018-0915-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40618-018-0915-z</ArticleId>
            <ArticleId IdType="pubmed">29923059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sabini E, Mazzi B, Profilo MA, Mautone T, Casini G, Rocchi R, Ionni I, Menconi F, Leo M, Nardi M, Vitti P, Marcocci C, Marinò M (2018) High Serum Cholesterol Is a Novel Risk Factor for Graves’ Orbitopathy: Results of a Cross-Sectional Study. Thyroid 28(3):386–394. https://doi.org/10.1089/thy.2017.0430</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2017.0430</ArticleId>
            <ArticleId IdType="pubmed">29336220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naselli A, Moretti D, Regalbuto C, Arpi ML, Lo GF, Frasca F, Belfiore A, Le Moli R (2020) Evidence That Baseline Levels of Low-Density Lipoproteins Cholesterol Affect the Clinical Response of Graves’ Ophthalmopathy to Parenteral Corticosteroids. Front Endocrinol (Lausanne) 11:609895. https://doi.org/10.3389/fendo.2020.609895</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fendo.2020.609895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun B, Zhang Z, Dong C, Zhang Y, Yan C, Li S (2017) 99Tcm-octreotide scintigraphy and serum eye muscle antibodies in evaluation of active thyroid-associated ophthalmopathy. Eye 31(5):668–676. https://doi.org/10.1038/eye.2017.42</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/eye.2017.42</ArticleId>
            <ArticleId IdType="pubmed">28387769</ArticleId>
            <ArticleId IdType="pmc">5437337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee JH, Park SH, Koh DG, Suh BK (2014) Thyroid peroxidase antibody positivity and triiodothyronine levels are associated with pediatric Graves’ ophthalmopathy. World J Pediatr 10(2):155–159. https://doi.org/10.1007/s12519-014-0476-y</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12519-014-0476-y</ArticleId>
            <ArticleId IdType="pubmed">24668239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marinò M, Rotondo Dottore G, Ionni I, Lanzolla G, Sabini E, Ricci D, Sframeli A, Mazzi B, Menconi F, Latrofa F, Vitti P, Marcocci C, Chiovato L (2019) Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves’ disease and Graves’ orbitopathy. J Endocrinol Invest 42(4):471–480. https://doi.org/10.1007/s40618-018-0943-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40618-018-0943-8</ArticleId>
            <ArticleId IdType="pubmed">30132285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diana T, Kahaly GJ (2018) Thyroid Stimulating Hormone Receptor Antibodies in Thyroid Eye Disease—Methodology and Clinical Applications. Ophthalmic Plast Reconstr Surg 34(4S):S13–S19. https://doi.org/10.1097/IOP.0000000000001053</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/IOP.0000000000001053</ArticleId>
            <ArticleId IdType="pubmed">29771755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lantz M, Planck T, Åsman P, Hallengren B (2014) Increased TRAb and/or Low Anti-TPO Titers at Diagnosis of Graves’ Disease are Associated with an Increased Risk of Developing Ophthalmopathy after Onset. Exp Clin Endocr Diab 122(02):113–117. https://doi.org/10.1055/s-0033-1363193</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0033-1363193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu SH, Kang JG, Kim CS, Ihm S, Choi MG, Yoo HJ, Lee SJ (2017) Clinical Implications of Immunoglobulin G4 to Graves’ Ophthalmopathy. Thyroid 27(9):1185–1193. https://doi.org/10.1089/thy.2017.0126</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2017.0126</ArticleId>
            <ArticleId IdType="pubmed">28805160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wiersinga W, Žarković M, Bartalena L, Donati S, Perros P, Okosieme O, Morris D, Fichter N, Lareida J, von Arx G, Daumerie C, Burlacu M, Kahaly G, Pitz S, Beleslin B, Ćirić J, Ayvaz G, Konuk O, Törüner FB, Salvi M, Covelli D, Curro N, Hegedüs L, Brix T (2018) Predictive score for the development or progression of Graves’ orbitopathy in patients with newly diagnosed Graves’ hyperthyroidism. Eur J Endocrinol 178(6):635–643. https://doi.org/10.1530/EJE-18-0039</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/EJE-18-0039</ArticleId>
            <ArticleId IdType="pubmed">29650691</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eckstein AK, Losch C, Glowacka D, Schott M, Mann K, Esser J, Morgenthaler NG (2009) Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetrical Graves ophthalmopathy. Brit J Ophthalmol 93(8):1052–1056. https://doi.org/10.1136/bjo.2007.137265</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bjo.2007.137265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shibayama K, Ohyama Y, Yokota Y, Ohtsu S, Takubo N, MATSUURA N, (2005) Assays for Thyroid-stimulating Antibodies and Thyrotropin-binding Inhibitory Immunoglobulins in Children with Graves’ Disease. Endocr J 52(5):505–510. https://doi.org/10.1507/endocrj.52.505</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1507/endocrj.52.505</ArticleId>
            <ArticleId IdType="pubmed">16284425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eckstein AK, Plicht M, Lax H, Neuhäuser M, Mann K, Lederbogen S, Heckmann C, Esser J, Morgenthaler NG, (2006) Thyrotropin Receptor Autoantibodies Are Independent Risk Factors for Graves’ Ophthalmopathy and Help to Predict Severity and Outcome of the Disease. J Clin Endocrinol Metab 91(9):3464–3470. https://doi.org/10.1210/jc.2005-2813</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2005-2813</ArticleId>
            <ArticleId IdType="pubmed">16835285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turcu AF, Kumar S, Neumann S, Coenen M, Iyer S, Chiriboga P, Gershengorn MC, Bahn RS (2013) A Small Molecule Antagonist Inhibits Thyrotropin Receptor Antibody-Induced Orbital Fibroblast Functions Involved in the Pathogenesis of Graves Ophthalmopathy. J Clin Endocrinol Metab 98(5):2153–2159. https://doi.org/10.1210/jc.2013-1149</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2013-1149</ArticleId>
            <ArticleId IdType="pubmed">23482611</ArticleId>
            <ArticleId IdType="pmc">3644605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Zeijl CJJ, Fliers E, van Koppen CJ, Surovtseva OV, de Gooyer ME, Mourits MP, Wiersinga WM, Miltenburg AMM, Boelen A (2011) Thyrotropin Receptor-Stimulating Graves’ Disease Immunoglobulins Induce Hyaluronan Synthesis by Differentiated Orbital Fibroblasts from Patients with Graves’ Ophthalmopathy Not Only Via Cyclic Adenosine Monophosphate Signaling Pathways. Thyroid 21(2):169–176. https://doi.org/10.1089/thy.2010.0123</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2010.0123</ArticleId>
            <ArticleId IdType="pubmed">20954819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumar S, Iyer S, Bauer H, Coenen M, Bahn RS (2012) A Stimulatory Thyrotropin Receptor Antibody Enhances Hyaluronic Acid Synthesis in Graves’ Orbital Fibroblasts: Inhibition by an IGF-I Receptor Blocking Antibody. J Clin Endocrinol Metab 97(5):1681–1687. https://doi.org/10.1210/jc.2011-2890</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2011-2890</ArticleId>
            <ArticleId IdType="pubmed">22399503</ArticleId>
            <ArticleId IdType="pmc">3339886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krieger CC, Place RF, Bevilacqua C, Marcus-Samuels B, Abel BS, Skarulis MC, Kahaly GJ, Neumann S, Gershengorn MC (2016) TSH/IGF-1 Receptor Cross Talk in Graves’ Ophthalmopathy Pathogenesis. J Clin Endocrinol Metab 101(6):2340–2347. https://doi.org/10.1210/jc.2016-1315</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2016-1315</ArticleId>
            <ArticleId IdType="pubmed">27043163</ArticleId>
            <ArticleId IdType="pmc">4891793</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Place RF, Krieger CC, Neumann S, Gershengorn MC (2017) Inhibiting thyrotropin/insulin-like growth factor 1 receptor crosstalk to treat Graves’ ophthalmopathy: studies in orbital fibroblastsin vitro. Brit J Pharmacol 174(4):328–340. https://doi.org/10.1111/bph.13693</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bph.13693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krieger CC, Boutin A, Jang D, Morgan SJ, Banga JP, Kahaly GJ, Klubo-Gwiezdzinska J, Neumann S, Gershengorn MC (2019) Arrestin-β-1 Physically Scaffolds TSH and IGF1 Receptors to Enable Crosstalk. Endocrinology 160(6):1468–1479. https://doi.org/10.1210/en.2019-00055</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/en.2019-00055</ArticleId>
            <ArticleId IdType="pubmed">31127272</ArticleId>
            <ArticleId IdType="pmc">6542485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumar S, Schiefer R, Coenen MJ, Bahn RS (2010) A Stimulatory Thyrotropin Receptor Antibody (M22) and Thyrotropin Increase Interleukin-6 Expression and Secretion in Graves’ Orbital Preadipocyte Fibroblasts. Thyroid 20(1):59–65. https://doi.org/10.1089/thy.2009.0278</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2009.0278</ArticleId>
            <ArticleId IdType="pubmed">20017620</ArticleId>
            <ArticleId IdType="pmc">2833174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng K, Wu Y, Cheng K, Cheng K, Chen K, Wu W, Lee P, Chang C (2018) Autoantibody against aldehyde dehydrogenase 2 could be a biomarker to monitor progression of Graves’ orbitopathy. Graefes Arch Clin Exp Ophthalmol 256(6):1195–1201. https://doi.org/10.1007/s00417-017-3894-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00417-017-3894-4</ArticleId>
            <ArticleId IdType="pubmed">29397435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Haan S, Lahooti H, Morris O, Wall JR (2010) Epitopes, immunoglobulin classes and immunoglobulin G subclasses of calsequestrin antibodies in patients with thyroid eye disease. Autoimmunity 43(8):698–703. https://doi.org/10.3109/08916931003774954</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/08916931003774954</ArticleId>
            <ArticleId IdType="pubmed">20670117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khamisi S, Lundqvist M, Emadi P, Almby K, Ljunggren O, Karlsson FA (2021) Serum thyroglobulin is associated with orbitopathy in Graves’ disease. J Endocrinol Invest 44(9):1905–1911. https://doi.org/10.1007/s40618-021-01505-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40618-021-01505-8</ArticleId>
            <ArticleId IdType="pubmed">33515213</ArticleId>
            <ArticleId IdType="pmc">8357771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuś A, Szymański K, Jurecka-Lubieniecka B, Pawlak-Adamska E, Kula D, Miśkiewicz P, Bolanowski M, Płoski R, Bossowski A, Daroszewski J, Jarząb B, Bednarczuk T (2017) Gender-dependent and age-of-onset-specific association of the rs11675434 single-nucleotide polymorphism near TPO with susceptibility to Graves’ ophthalmopathy. J Hum Genet 62(3):373–377. https://doi.org/10.1038/jhg.2016.135</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/jhg.2016.135</ArticleId>
            <ArticleId IdType="pubmed">27829681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Profilo MA, Sisti E, Marcocci C, Vitti P, Pinchera A, Nardi M, Rocchi R, Latrofa F, Menconi F, Altea MA, Leo M, Rago T, Marinò M (2013) Thyroid Volume and Severity of Graves’ Orbitopathy. Thyroid 23(1):97–102. https://doi.org/10.1089/thy.2012.0379</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2012.0379</ArticleId>
            <ArticleId IdType="pubmed">23088654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jang SY, Lee KH, Oh JR, Kim BY, Yoon JS (2015) Development of Thyroid-Associated Ophthalmopathy in Patients Who Underwent Total Thyroidectomy. Yonsei Med J 56(5):1389. https://doi.org/10.3349/ymj.2015.56.5.1389</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3349/ymj.2015.56.5.1389</ArticleId>
            <ArticleId IdType="pubmed">26256985</ArticleId>
            <ArticleId IdType="pmc">4541672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Menconi F, Marinò M, Pinchera A, Rocchi R, Mazzi B, Nardi M, Bartalena L, Marcocci C, (2007) Effects of Total Thyroid Ablation Versus Near-Total Thyroidectomy Alone on Mild to Moderate Graves’ Orbitopathy Treated with Intravenous Glucocorticoids. J Clin Endocrinol Metab 92(5):1653–1658. https://doi.org/10.1210/jc.2006-1800</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2006-1800</ArticleId>
            <ArticleId IdType="pubmed">17299076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stan MN, Durski JM, Brito JP, Bhagra S, Thapa P, Bahn RS (2013) Cohort Study on Radioactive Iodine–Induced Hypothyroidism: Implications for Graves' Ophthalmopathy and Optimal Timing for Thyroid Hormone Assessment. Thyroid (New York, N.Y.) 23(5):62–625. https://doi.org/10.1089/thy.2012.0258</Citation>
        </Reference>
        <Reference>
          <Citation>Fernando R, Placzek E, Reese EA, Placzek AT, Schwartz S, Trierweiler A, Niziol LM, Raychaudhuri N, Atkins S, Scanlan TS, Smith TJ (2017) Elevated Serum Tetrac in Graves Disease: Potential Pathogenic Role in Thyroid-Associated Ophthalmopathy. J Clin Endocrinol Metab 102(3):776–785. https://doi.org/10.1210/jc.2016-2762</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2016-2762</ArticleId>
            <ArticleId IdType="pubmed">27768856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jarusaitiene D, Verkauskiene R, Jasinskas V, Jankauskiene J (2016) Predictive Factors of Development of Graves’ Ophthalmopathy for Patients with Juvenile Graves’ Disease. Int J Endocrinol 2016:1–9. https://doi.org/10.1155/2016/8129497</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2016/8129497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, Fleming JC, Fowler BT, Marcocci C, Marinò M, Antonelli A, Dailey R, Harris GJ, Eckstein A, Schiffman J, Tang R, Nelson C, Salvi M, Wester S, Sherman JW, Vescio T, Holt RJ, Smith TJ (2020) Teprotumumab for the Treatment of Active Thyroid Eye Disease. New Engl J Med 382(4):341–352. https://doi.org/10.1056/NEJMoa1910434</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1910434</ArticleId>
            <ArticleId IdType="pubmed">31971679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soeters MR, van Zeijl CJ, Boelen A, Kloos R, Saeed P, Vriesendorp TM, Mourits MP (2011) Optimal management of Graves orbitopathy: a multidisciplinary approach. Neth J Med 69(7):302–308</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21934174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pawlak-Adamska E, Frydecka I, Bolanowski M, Tomkiewicz A, Jonkisz A, Karabon L, Partyka A, Nowak O, Szalinski M, Daroszewski J (2017) CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves’ disease and modulates clinical phenotype of disease. Endocrine 55(1):186–199. https://doi.org/10.1007/s12020-016-1096-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12020-016-1096-1</ArticleId>
            <ArticleId IdType="pubmed">27638540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen D, Chu Y, Wen Y, Lin W, Hour A, Wang W (2019) Investigation of the Correlation between Graves’ Ophthalmopathy and CTLA4 Gene Polymorphism. J Clin Med 8(11):1842. https://doi.org/10.3390/jcm8111842</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/jcm8111842</ArticleId>
            <ArticleId IdType="pmc">6912222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Q, Yang YM, Lv XY (2006) Association of Graves’ disease and Graves’ ophthalmopathy with the polymorphisms in promoter and exon 1 of cytotoxic T lymphocyte associated antigen-4 gene. J Zhejiang Univ Sci B 7(11):887–891. https://doi.org/10.1631/jzus.2006.B0887</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1631/jzus.2006.B0887</ArticleId>
            <ArticleId IdType="pubmed">17048303</ArticleId>
            <ArticleId IdType="pmc">1635815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y, Chen R, Chen W, Tsai Y, Wan L, Tsai F (2010) Disease Association of the CD103 Polymorphisms in Taiwan Chinese Graves’ Ophthalmopathy Patients. Ophthalmology 117(8):1645–1651. https://doi.org/10.1016/j.ophtha.2009.12.037</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ophtha.2009.12.037</ArticleId>
            <ArticleId IdType="pubmed">20417566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liao W, Chen R, Lin H, Liu Y, Chen W, Tsai Y, Wan L, Tsai F (2011) The Association between Polymorphisms of B7 Molecules (CD80 and CD86) and Graves’ Ophthalmopathy in a Taiwanese Population. Ophthalmology 118(3):553–557. https://doi.org/10.1016/j.ophtha.2010.07.021</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ophtha.2010.07.021</ArticleId>
            <ArticleId IdType="pubmed">20884055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong KH, Rong SS, Chong KKL, Young AL, Pang CP, Chen LJ (2015) Genetic Associations of Interleukin-related Genes with Graves’ Ophthalmopathy: a Systematic Review and Meta-analysis. Sci Rep-Uk 5(1):16672. https://doi.org/10.1038/srep16672</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep16672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khalilzadeh O, Anvari M, Esteghamati A, Mahmoudi M, Tahvildari M, Rashidi A, Khosravi F, Amirzargar A (2009) Graves’ ophthalmopathy and gene polymorphisms in interleukin-1α, interleukin-1β, interleukin-1 receptor and interleukin-1 receptor antagonist. Clin Experiment Ophthalmol 37(6):614–619. https://doi.org/10.1111/j.1442-9071.2009.02093.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1442-9071.2009.02093.x</ArticleId>
            <ArticleId IdType="pubmed">19702713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gu L, Jia H, Zhao Y, Liu N, Wang S, Cui B, Ning G (2009) Association studies of interleukin-8 gene in Graves’ disease and Graves’ ophthalmopathy. Endocrine 36(3):452–456. https://doi.org/10.1007/s12020-009-9240-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12020-009-9240-9</ArticleId>
            <ArticleId IdType="pubmed">19816813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anvari M, Khalilzadeh O, Esteghamati A, Esfahani SA, Rashidi A, Etemadi A, Mahmoudi M, Amirzargar AA (2010) Genetic susceptibility to Graves’ ophthalmopathy: the role of polymorphisms in proinflammatory cytokine genes. Eye 24(6):1058–1063. https://doi.org/10.1038/eye.2009.244</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/eye.2009.244</ArticleId>
            <ArticleId IdType="pubmed">19798110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu W, Liu N, Zhao Y, Jia H, Cui B, Ning G (2010) Association analysis of polymorphisms in IL-3, IL-4, IL-5, IL-9, and IL-13 with Graves’ disease. J Endocrinol Invest 33(10):751–755. https://doi.org/10.1007/BF03346682</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF03346682</ArticleId>
            <ArticleId IdType="pubmed">20332709</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jia HY, Zhang ZG, Gu XJ, Guo T, Cui B, Ning G, Zhao YJ (2011) Association between interleukin 21 and Graves’ disease. Genet Mol Res 10(4):3338–3346. https://doi.org/10.4238/2011.October.31.6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4238/2011.October.31.6</ArticleId>
            <ArticleId IdType="pubmed">22057994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang H, Wang Y, Bao J, Wang S, Lei P, Sun Z (2017) Correlation of HLA-DQ and TNF-α gene polymorphisms with ocular myasthenia gravis combined with thyroid-associated ophthalmopathy. Bioscience Rep 37(2)10.1042/BSR20160440</Citation>
        </Reference>
        <Reference>
          <Citation>Yan SL, Wang YX (2005) The relevance of tumor necrosis factor-alpha gene-863C/A polymorphism with thyroid-associated ophthalmopathy. Zhonghua Yan Ke Za Zhi 41(9):786–790</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16191343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsai K, Tsai F, Lin H, Lin H, Liu Y, Liao W, Wan L (2012) Thymic stromal lymphopoietin gene promoter polymorphisms and expression levels in Graves’ disease and Graves’ ophthalmopathy. Bmc Med Genet 13(1):116. https://doi.org/10.1186/1471-2350-13-116</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2350-13-116</ArticleId>
            <ArticleId IdType="pubmed">23194010</ArticleId>
            <ArticleId IdType="pmc">3582428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bufalo NE, Dos Santos RB, Marcello MA, Piai RP, Secolin R, Romaldini JH, Ward LS (2015) TSHR intronic polymorphisms (rs179247 and rs12885526) and their role in the susceptibility of the Brazilian population to Graves’ disease and Graves’ ophthalmopathy. J Endocrinol Invest 38(5):555–561. https://doi.org/10.1007/s40618-014-0228-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40618-014-0228-9</ArticleId>
            <ArticleId IdType="pubmed">25543543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pawlak-Adamska E, Daroszewski J, Bolanowski M, Oficjalska J, Janusz P, Szalinski M, Frydecka I (2013) PPARg2 Ala12 variant protects against Graves’ orbitopathy and modulates the course of the disease. Immunogenetics 65(7):493–500. https://doi.org/10.1007/s00251-013-0702-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00251-013-0702-0</ArticleId>
            <ArticleId IdType="pubmed">23604462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee JY, Kim NK, Cho YW, Lew H (2016) Association between methylenetetrahydrofolate reductase (MTHFR) polymorphisms and susceptibility to Graves’ ophthalmopathy. Mol Med Rep 14(3):2276–2282. https://doi.org/10.3892/mmr.2016.5458</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/mmr.2016.5458</ArticleId>
            <ArticleId IdType="pubmed">27430300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu T, Tang D, Zhao L, Sun F (2018) Poly (ADP-ribose) polymerase-1 (PARP-1) in Chinese patients with Graves’ disease and Graves’ ophthalmopathy. Can J Physiol Pharm 96(6):556–561. https://doi.org/10.1139/cjpp-2016-0332</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1139/cjpp-2016-0332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Niyazoglu M, Baykara O, Koc A, Aydoğdu P, Onaran I, Dellal FD, Tasan E, Sultuybek GK (2014) Association of PARP-1, NF-κB, NF-κBIA and IL-6, IL-1β and TNF-α with Graves Disease and Graves Ophthalmopathy. Gene 547(2):226–232. https://doi.org/10.1016/j.gene.2014.06.038</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gene.2014.06.038</ArticleId>
            <ArticleId IdType="pubmed">24956560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y, Chen Y, Wu H, Wang T, Tsai F (2014) Single Nucleotide Polymorphisms at the PRR3, ABCF1, and GNL1 Genes in the HLA Class I Region Are Associated with Graves’ Ophthalmopathy in a Gender-Dependent Manner. Ophthalmology 121(10):2033–2039. https://doi.org/10.1016/j.ophtha.2014.04.027</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ophtha.2014.04.027</ArticleId>
            <ArticleId IdType="pubmed">24908204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khong JJ, Burdon KP, Lu Y, Leonardos L, Laurie KJ, Walsh JP, Gajdatsy AD, Ebeling PR, McNab AA, Hardy TG, Stawell RJ, Davis GJ, Selva D, Tsirbas A, Montgomery GW, Macgregor S, Craig JE (2016) Association of Polymorphisms in MACRO Domain Containing 2 With Thyroid-Associated Orbitopathy. Investigative Opthalmology &amp; Visual Science 57(7):3129. https://doi.org/10.1167/iovs.15-18797</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1167/iovs.15-18797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan R, Yang J, Jiang P, Jin L, Ma J, Huang R, Ma N, Jiang F (2015) Genetic variations in the SOCS3 gene in patients with Graves’ ophthalmopathy. J Clin Pathol 68(6):448–452. https://doi.org/10.1136/jclinpath-2014-202751</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jclinpath-2014-202751</ArticleId>
            <ArticleId IdType="pubmed">25770161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stan MN, Bahn RS (2010) Risk Factors for Development or Deterioration of Graves’ Ophthalmopathy. Thyroid 20(7):777–783. https://doi.org/10.1089/thy.2010.1634</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2010.1634</ArticleId>
            <ArticleId IdType="pubmed">20578901</ArticleId>
            <ArticleId IdType="pmc">3357079</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
